AD/PD 2019, the 14th International Conference on Alzheimer's and Parkinson's Diseases Mar 26, 2019 20190326 Mar 31, 2019 Lisbon, Portugal The AD/PDTM meeting will take place in Lisbon, Portugal, one of the most classical cities in Europe. The conference will build on the well-earned reputation of previous AD/PDTM Conferences. The ground breaking series of Alzheimer's and Parkinson's Diseases Conferences attract international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. AD/PDTM Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention, and therapy. The remarkable success of the series of AD/PDTM Conferences is evident from the progressive increases from one Conference to the next, in the number of participants, over 3,217 in Vienna in 2017, the number of countries represented, 66 in Vienna, and the ratio of individuals below the age of 35 to that of the rest of the group. At AD/PDTM 2019 in Lisbon we anticipate an attendance of more than 3500 participants. /content/dam/pmiscience/default-fallback-thumbnails/conference/pmi-science-inside-laboratory-fallback.png

      AD/PD 2019, the 14th International Conference on Alzheimer's and Parkinson's Diseases

      Date
      Mar 26, 2019 - Mar 31, 2019
      Location
      Lisbon, Portugal
      The AD/PDTM meeting will take place in Lisbon, Portugal, one of the most classical cities in Europe. The conference will build on the well-earned reputation of previous AD/PDTM Conferences. The ground breaking series of Alzheimer's and Parkinson's Diseases Conferences attract international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer's, Parkinson's and other related neurodegenerative diseases. AD/PDTM Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; a strong focus is mechanisms of disease, prevention, and therapy. The remarkable success of the series of AD/PDTM Conferences is evident from the progressive increases from one Conference to the next, in the number of participants, over 3,217 in Vienna in 2017, the number of countries represented, 66 in Vienna, and the ratio of individuals below the age of 35 to that of the rest of the group. At AD/PDTM 2019 in Lisbon we anticipate an attendance of more than 3500 participants.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.